Literature DB >> 35012328

National Institutes of Health Stroke Scale as an Outcome in Stroke Research: Value of ANCOVA Over Analyzing Change From Baseline.

Eva A Mistry1, Sharon D Yeatts2, Pooja Khatri1, Akshitkumar M Mistry3, Michelle Detry4, Kert Viele4, Frank E Harrell5, Roger J Lewis4,6,7.   

Abstract

National Institutes of Health Stroke Scale (NIHSS), measured a few hours to days after stroke onset, is an attractive outcome measure for stroke research. NIHSS at the time of presentation (baseline NIHSS) strongly predicts the follow-up NIHSS. Because of the need to account for the baseline NIHSS in the analysis of follow-up NIHSS as an outcome measure, a common and intuitive approach is to define study outcome as the change in NIHSS from baseline to follow-up (ΔNIHSS). However, this approach has important limitations. Analyzing ΔNIHSS implies a very strong assumption about the relationship between baseline and follow-up NIHSS that is unlikely to be satisfied, drawing into question the validity of the resulting statistical analysis. This reduces the precision of the estimates of treatment effects and the power of clinical trials that use this approach to analysis. ANCOVA allows for the analysis of follow-up NIHSS as the dependent variable while adjusting for baseline NIHSS as a covariate in the model and addresses several challenges of using ΔNIHSS outcome using simple bivariate comparisons (eg, a t test, Wilcoxon rank-sum, linear regression without adjustment for baseline) for stroke research. In this article, we use clinical trial simulations to illustrate that variability in NIHSS outcome is less when follow-up NIHSS is adjusted for baseline compared to ΔNIHSS and how a reduction in this variability improves the power. We outline additional, important clinical and statistical arguments to support the superiority of ANCOVA using the final measurement of the NIHSS adjusted for baseline over, and caution against using, the simple bivariate comparison of absolute NIHSS change (ie, delta).

Entities:  

Keywords:  National Institutes of Health (US); goal; ischemic stroke; patients; statistics

Mesh:

Year:  2022        PMID: 35012328      PMCID: PMC8960347          DOI: 10.1161/STROKEAHA.121.034859

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Rapid Neurologic Improvement Predicts Favorable Outcome 90 Days After Thrombectomy in the DEFUSE 3 Study.

Authors:  Jeremy J Heit; Michael Mlynash; Stephanie M Kemp; Maarten G Lansberg; Soren Christensen; Michael P Marks; Santiago Ortega-Gutierrez; Gregory W Albers
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

2.  Prognostic Value of the 24-Hour Neurological Examination in Anterior Circulation Ischemic Stroke: A post hoc Analysis of Two Randomized Controlled Stroke Trials.

Authors:  Srikant Rangaraju; Michael Frankel; Tudor G Jovin
Journal:  Interv Neurol       Date:  2016-02-19

3.  Neurologic worsening during the acute phase of ischemic stroke.

Authors:  Christian Weimar; Thomas Mieck; Joachim Buchthal; Christiane E Ehrenfeld; Elisabeth Schmid; Hans-Christoph Diener
Journal:  Arch Neurol       Date:  2005-03

Review 4.  Clinical interpretation and use of stroke scales.

Authors:  Scott E Kasner
Journal:  Lancet Neurol       Date:  2006-07       Impact factor: 44.182

5.  Comparisons against baseline within randomised groups are often used and can be highly misleading.

Authors:  J Martin Bland; Douglas G Altman
Journal:  Trials       Date:  2011-12-22       Impact factor: 2.279

6.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Characteristics of the National Institute of Health Stroke Scale: results from a population-based stroke cohort at baseline and after one year.

Authors:  Peter Appelros; Andreas Terént
Journal:  Cerebrovasc Dis       Date:  2003-10-03       Impact factor: 2.762

9.  Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial.

Authors:  Larry B Goldstein; Laura Lennihan; Meheroz J Rabadi; David C Good; Michael J Reding; Alexander W Dromerick; Gregory P Samsa; John Pura
Journal:  JAMA Neurol       Date:  2018-12-01       Impact factor: 18.302

10.  Effect of Endovascular Contact Aspiration vs Stent Retriever on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion: The ASTER Randomized Clinical Trial.

Authors:  Bertrand Lapergue; Raphael Blanc; Benjamin Gory; Julien Labreuche; Alain Duhamel; Gautier Marnat; Suzana Saleme; Vincent Costalat; Serge Bracard; Hubert Desal; Mikael Mazighi; Arturo Consoli; Michel Piotin
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.